Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 246

1.

Fluence rate as a modulator of PDT mechanisms.

Henderson BW, Busch TM, Snyder JW.

Lasers Surg Med. 2006 Jun;38(5):489-93. Review.

PMID:
16615136
2.

Photodynamic therapy creates fluence rate-dependent gradients in the intratumoral spatial distribution of oxygen.

Busch TM, Wileyto EP, Emanuele MJ, Del Piero F, Marconato L, Glatstein E, Koch CJ.

Cancer Res. 2002 Dec 15;62(24):7273-9.

3.

Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors.

Henderson BW, Gollnick SO, Snyder JW, Busch TM, Kousis PC, Cheney RT, Morgan J.

Cancer Res. 2004 Mar 15;64(6):2120-6.

4.

Photodynamic therapy for malignant mesothelioma: preclinical studies for optimization of treatment protocols.

Schouwink H, Ruevekamp M, Oppelaar H, van Veen R, Baas P, Stewart FA.

Photochem Photobiol. 2001 Apr;73(4):410-7.

PMID:
11332037
5.

The effect of fluence rate on tumor and normal tissue responses to photodynamic therapy.

Sitnik TM, Henderson BW.

Photochem Photobiol. 1998 Apr;67(4):462-6.

PMID:
9559590
6.

Potentiation of photodynamic therapy antitumor activity in mice by nitric oxide synthase inhibition is fluence rate dependent.

Henderson BW, Sitnik-Busch TM, Vaughan LA.

Photochem Photobiol. 1999 Jul;70(1):64-71.

PMID:
10420844
8.

Effect of photosensitizer dose on fluence rate responses to photodynamic therapy.

Wang HW, Rickter E, Yuan M, Wileyto EP, Glatstein E, Yodh A, Busch TM.

Photochem Photobiol. 2007 Sep-Oct;83(5):1040-8.

PMID:
17880498
9.
10.

Light dosimetry for intraperitoneal photodynamic therapy in a murine xenograft model of human epithelial ovarian carcinoma.

Lilge L, Molpus K, Hasan T, Wilson BC.

Photochem Photobiol. 1998 Sep;68(3):281-8.

PMID:
9747583
11.

Treatment-induced changes in tumor oxygenation predict photodynamic therapy outcome.

Wang HW, Putt ME, Emanuele MJ, Shin DB, Glatstein E, Yodh AG, Busch TM.

Cancer Res. 2004 Oct 15;64(20):7553-61.

12.

Monitoring interstitial m-THPC-PDT in vivo using fluorescence and reflectance spectroscopy.

Kruijt B, van der Ploeg-van den Heuvel A, de Bruijn HS, Sterenborg HJ, Amelink A, Robinson DJ.

Lasers Surg Med. 2009 Nov;41(9):653-64. doi: 10.1002/lsm.20845.

PMID:
19802884
13.

Optimisation of illumination for photodynamic therapy with mTHPC on normal colon and a transplantable tumour in rats.

Tsutsui H, MacRobert AJ, Curnow A, Rogowska A, Buonaccorsi G, Kato H, Bown SG.

Lasers Med Sci. 2002;17(2):101-9.

PMID:
12111593
14.

Photodynamic therapy of actinic keratosis at varying fluence rates: assessment of photobleaching, pain and primary clinical outcome.

Ericson MB, Sandberg C, Stenquist B, Gudmundson F, Karlsson M, Ros AM, Rosén A, Larkö O, Wennberg AM, Rosdahl I.

Br J Dermatol. 2004 Dec;151(6):1204-12.

PMID:
15606516
15.

The role of oxygen monitoring during photodynamic therapy and its potential for treatment dosimetry.

Woodhams JH, Macrobert AJ, Bown SG.

Photochem Photobiol Sci. 2007 Dec;6(12):1246-56. Epub 2007 Sep 21.

PMID:
18046479
16.
17.

Predictions of mathematical models of tissue oxygenation and generation of singlet oxygen during photodynamic therapy.

Yuan J, Mahama-Relue PA, Fournier RL, Hampton JA.

Radiat Res. 1997 Oct;148(4):386-94. Review.

PMID:
9339955
18.

Long-term regression of the murine mammary adenocarcinoma, LM3, by repeated photodynamic treatments using meso-tetra (4-N-methylpyridinium) porphine.

Colombo LL, Vanzulli SI, Villanueva A, Cañete M, Juarranz A, Stockert JC.

Int J Oncol. 2005 Oct;27(4):1053-9.

PMID:
16142323
19.

Hypericin-photodynamic therapy (PDT) using an alternative treatment regime suitable for multi-fraction PDT.

Thong PS, Watt F, Ren MQ, Tan PH, Soo KC, Olivo M.

J Photochem Photobiol B. 2006 Jan 2;82(1):1-8. Epub 2005 Oct 3.

PMID:
16203156
20.

Foscan-based photodynamic treatment in vivo: correlation between efficacy and Foscan accumulation in tumor, plasma and leukocytes.

Maugain E, Sasnouski S, Zorin V, Merlin JL, Guillemin F, Bezdetnaya L.

Oncol Rep. 2004 Sep;12(3):639-45.

PMID:
15289849

Supplemental Content

Support Center